Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept vs Placebo with FOLFIRI in Metastatic Colorectal Cancer (AFLAME)
NCT01661270Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jul 2012
- Primary completion
- Oct 2014
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial in metastatic colorectal cancer (mCRC) comparing Aflibercept + FOLFIRI with Placebo + FOLFIRI (2 arms). Primary endpoint: Progression-Free Survival at 26.7 months. Started Jul 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01661270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661270.